#SFHS2613663AFrance Adds TWICOR 5 mg/10 mg to the Public-Sector Approved Medicines List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
France adds two TWICOR 5 mg/10 mg presentations to the list of medicines approved for use by public institutions and public services. The product combines rosuvastatin and ezetimibe and is listed in 30-tablet and 90-tablet packs from Viatris Santé. Health insurance coverage is limited to one use: treating primary hypercholesterolemia in adults whose condition is already well controlled, as a replacement for taking the two separate ingredients together at the same doses.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds TWICOR 5 mg/10 mg to the approved medicines list for public institutions and public services
- Covers two pack sizes: 30 tablets and 90 tablets
- Limits reimbursement to primary hypercholesterolemia treatment in controlled adult patients replacing separate rosuvastatin and ezetimibe use
Obligations
What this law requires
Public institutions and public services may use the approved-list status only for the two TWICOR 5 mg/10 mg presentations identified by CIP codes 34009 303 275 2 4 and 34009 303 275 3 1, respectively the 30-tablet and 90-tablet blister packs from Viatris Santé.
Health insurance coverage for the listed TWICOR 5 mg/10 mg presentations is limited to treatment of primary hypercholesterolemia, as an adjunct to diet, in adult patients whose condition is adequately controlled and where TWICOR replaces concomitant use of rosuvastatin and ezetimibe taken separately at the same doses.